WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical…
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of…
Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocolQ2 2023 consolidated revenue were affected by specialty…
Accomplished Industry Veteran Brings Deep Strategic and Operational ExpertiseCAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq:…
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a…
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled…
NEW YORK and LEAMINGTON, Ontario, July 12, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY;…
The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to…
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern TimeNEW YORK, July 12,…
Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010…